About Cerenome / Partnerships

Partner with a company built for CNS oncology.

Cerenome works with organizations that share a commitment to changing central nervous system (CNS) cancer outcomes: research institutions, clinical collaborators, and industry partners who see the same opportunity we do in a space long overlooked.

Why Cerenome

More than a single asset; a platform.

An integrated platform, uniting diagnostics, therapeutics, and data, offers more surface area to collaborate against: detection, treatment, and the evidence that connects them. And because CNS oncology is our entire focus, partners get depth and dedication in a space most companies treat as peripheral.

Diagnostics

A sequencing collaboration that will extend CNSide® to DNA and RNA profiling across hundreds of clinically relevant targets, from the same cerebrospinal fluid (CSF) sample.

Therapeutics

ReSPECT™ Phase 1 ran as a multicenter study across leading CNS cancer centers, with results published in Nature Communications.

Data Insights

A joint cost-of-care analysis found that earlier leptomeningeal metastases detection using CNSide® could reduce related healthcare costs by 33%–47%. The poster was recognized among the top 5% of ISPOR 2026 presentations.

Partnership Opportunities

Where we collaborate.

We pursue partnerships across several areas. Across all of them, we look for partners aligned on CNS oncology and on integrated, evidence-led development.

Clinical and research collaboration.

We work with academic centers and investigators on trial sites, translational research, and co-authored publications across the ReSPECT™ program’s three indications.

Licensing.

We consider rights arrangements for our targeted radiotherapeutic technology, including applications beyond the central nervous system, such as the preclinical 188RNL-BAM program in solid tumors.

Commercial and distribution.

We partner with organizations that can extend our diagnostics and, in time, our therapeutics into centers and geographies we don’t reach on our own.

Diagnostics access.

We work with health systems, laboratory networks, and payers to make CSF testing easier to order, reimburse, and integrate into how CNS cancers are diagnosed.

Talk to the team.

Send an outline of what you have in mind, the capability it touches, and the stage you’re at. Partnership inquiries go directly to the team that evaluates them.